Sorafenib inhibits ABCG2 and overcomes irinotecan resistance−response

Autor: Céline Gongora
Přispěvatelé: Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Sorafenib
Cancer Research
Abcg2
[SDV.CAN]Life Sciences [q-bio]/Cancer
Pharmacology
urologic and male genital diseases
03 medical and health sciences
0302 clinical medicine
Colorectal Neoplasms/*drug therapy
medicine
Distribution (pharmacology)
Animals
Humans
heterocyclic compounds
Neoplasm Proteins/*genetics
neoplasms
ComputingMilieux_MISCELLANEOUS
030304 developmental biology
0303 health sciences
biology
Chemistry
Resistance response
ATP-Binding Cassette Transporters/*genetics
Camptothecin/*analogs & derivatives
Phenylurea Compounds/*administration & dosage
Blood proteins
female genital diseases and pregnancy complications
digestive system diseases
3. Good health
Irinotecan
Niacinamide/*analogs & derivatives
Oncology
030220 oncology & carcinogenesis
biology.protein
Steady state (chemistry)
medicine.drug
Zdroj: Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2014, 13, pp.764. ⟨10.1158/1535-7163.MCT-13-1026⟩
ISSN: 1535-7163
1538-8514
DOI: 10.1158/1535-7163.MCT-13-1026⟩
Popis: We are aware that sorafenib binds to plasma proteins. At steady state, when sorafenib is orally administered at 800 mg/d, accumulation ratios are 5.7 to 6.4, indicating that it has a good distribution range. Of note, 90% of sorafenib is bound to the plasma proteins ([1][1]), but the large
Databáze: OpenAIRE
Externí odkaz: